Garetosmab
COURAGE
Regeneron · Phase 2 · Active, not recruiting · Enrollment 1005
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| Trevogrumab | n/r | n/r | n/r | n/r |
| Arm A0 | n/r | n/r | n/r | n/r |
| Arm A1 | n/r | n/r | n/r | n/r |
| Arm B0 | n/r | n/r | n/r | n/r |
| Arm B1 | n/r | n/r | n/r | n/r |
| Arm C0 | n/r | n/r | n/r | n/r |
| Arm C1 | n/r | n/r | n/r | n/r |
| Arm D0 | n/r | n/r | n/r | n/r |
| Arm D1 | n/r | n/r | n/r | n/r |
| Arm 1 | n/r | n/r | n/r | n/r |
| Arm 2 | n/r | n/r | n/r | n/r |
| Arm 3 | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- Trevogrumab: endpoint not reported
- Arm A0: endpoint not reported
- Arm A1: endpoint not reported
- Arm B0: endpoint not reported
- Arm B1: endpoint not reported
- Arm C0: endpoint not reported
- Arm C1: endpoint not reported
- Arm D0: endpoint not reported
- Arm D1: endpoint not reported
- Arm 1: endpoint not reported
- Arm 2: endpoint not reported
- Arm 3: endpoint not reported